{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.52","value":"28.1"}]}],"title":"ADC"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.73","value":"31.7"}]}],"title":"TAb"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Cmax was derived from the PK blood samples collected.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set (PKAS) included all participants in the PK cohort who had received at least 3 of 4 doses up through Cycle 2 Day 1, and had at least 5 blood samples collected and assayed for measurement of ADC, TAb or unconjugated MMAE serum/plasma concentrations to determine at least 1 PK parameter.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)","title":"Pharmacokinetics (PK) of Antibody-Drug Conjugate (ADC), Total Antibody (TAb), in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1","type":"PRIMARY","unitOfMeasure":"micrograms per milliliter (ug/mL)"}